Skip to content

Hepatic De Novo Lipogenesis (DNL)in the Pathogenesis of Hepatic Steatosis in Obese Youth

The Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis in Obese Children and Adolescents

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01725035
Acronym
DNL
Enrollment
60
Registered
2012-11-12
Start date
2010-12-31
Completion date
2022-08-10
Last updated
2023-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver, Hepatic Steatosis

Keywords

De Novo Lipogenesis, Fatty Liver, Hepatic Steatosis, Gene variants

Brief summary

Nonalcoholic Fatty Liver Disease (NAFLD) is becoming the most common cause of liver disease in pediatrics, but little is known about its pathophysiology in children. While studies in obese adults with hepatic steatosis have described an increased hepatic de novo lipogenesis (DNL) depending on the diet, there are no studies exploring the mechanisms by which excess hepatic triglycerides increases in obese youths, thus explaining the accompanying dyslipidemia and the metabolic syndrome. The central hypothesis of this study is that hepatic conversion of carbohydrates to lipid (DNL) is enhanced and associated with accumulation of excess liver fat, dyslipidemia and hepatic insulin resistance in obese youths with hepatic steatosis. The overall goal is to examine whether hepatic DNL is increased in obese youths with steatosis compared to matched controls without steatosis. Hypotheses: Hepatic conversion of carbohydrates to lipid (DNL) is enhanced and is associated with accumulation of excess liver fat, dyslipidemia and hepatic insulin resistance in obese youths with hepatic steatosis.

Detailed description

In this study obese youths, adolescents and young adults (12-30 years) will undergo MRI (magnetic resonance imaging) measurement of liver lipid content to determine hepatic fat content. They will undergo a sugary drink (75 grams of glucose and 25 grams of fructose) challenge and Hepatic de novo lipogenesis will be determined as the incorporation of deuterium, from deuterium labeled water (D2O), into plasma triglycerides. Subjects will undergo a 6 hours study assessing de novo lipogenesis, an oral glucose tolerance test, dual energy x-ray absorptiometry, magnetic resonance imaging, and Euglycemic-Hyperinsulinemic Clamp. This study record has been re-opened in 2019 and updated to reflect any changes having remained open since its inception with the Yale University IRB and also having obtained additional funding though NIDDK.

Interventions

None listed

Sponsors

American Heart Association
CollaboratorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* Cases will meet the following criteria: * BMI higher than 75th percentile * Hepatic fat fraction (the amount of fat into the liver) greater or equal than 5.5% * Absence of any endocrinopathy * Absence of any therapy with medication known to alter glucose metabolism Controls will meet the following criteria: * BMI higher than 75th percentile * Hepatic fat fraction (the amount of fat into the liver) lower than 5.5% * Absence of any endocrinopathy * Absence of any therapy with medication known to alter glucose metabolism * Absence of any therapy with medication known to alter glucose metabolism

Exclusion criteria

* BMI under the 75th percentile * Hepatic fat fraction (the amount of fat into the liver) less than 5.5% * Absence of any endocrinopathy * Any therapy with medication known to alter glucose metabolism Controls will meet the following criteria: * BMI under the 75th percentile * Hepatic fat fraction (the amount of fat into the liver) greater than or equal to 5.5% * Any endocrinopathy * Any therapy with medication known to alter glucose metabolism

Design outcomes

Primary

MeasureTime frame
de novo lipogenesis response to high carbohydrate meal in obese kids with fatty liverStudy visit 3

Secondary

MeasureTime frame
de novo lipogenesis response to high carbohydrate meal in obese kids without fatty liverStudy visit 3

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026